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Abstract
Background: When abnormalities are found during the anatomy scan most patients are offered
amniocentesis and conventional karyotyping, using Giemsa (G)-banding of metaphase chromosomes to
detect aneuploidies and large structural changes in the prenatal diagnosis. The use of fluorescent in situ
hybridization (FISH) reduces the time to obtain a result because culture is not necessary, but can only detect
a limited number of prespecified targets. Small studies have shown that array comparative genomic
hybridization (aCGH) can detect all unbalanced chromosomal abnormalities as well as smaller deletions and
duplications that cannot be detected with routine cytogenetic analysis. Should aCGH screening be used
instead of karyotyping to diagnose prenatal chromosomal abnormalities in pregnant patients with abnormal
ultrasound?
Methods: An exhaustive search of available medical literature from the past 5 years was conducted using
Medline-OVID, CINAHL, Web of Science. Key words included: comparative genomic hybridization,
pregnancy, abnormal ultrasound, prenatal ultrasound and ultrasound. Relevant articles were assessed for
quality using GRADE.
Results: Two studies met inclusion criteria and were used in this review. The first is a large prospective,
comparison to gold standard (karyotyping). This study compared prenatal diagnostic samples, and found
microarray (aCGH) was equivalent to standard karyotype analysis for common aneuploidies and found
additional clinically relevant information when patients had abnormal ultrasounds. The second study was a
prospective study of over 5000 pregnancies and again additional clinical significant findings were found using
aCGH.
Conclusion: Array comparative genomic hybridization should be considered for all patients who wish to
undergo invasive prenatal screening and should be offered to all patients with abnormal prenatal ultrasounds.
Adequate genetic counseling should be provided by a trained professional in all cases. A cost analysis should
be done comparing tests.
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Abstract   
Background: When abnormalities are found during the anatomy scan most patients are 
offered amniocentesis and conventional karyotyping, using Giemsa (G)-banding of 
metaphase chromosomes to detect aneuploidies and large structural changes in the 
prenatal diagnosis. The use of fluorescent in situ hybridization (FISH) reduces the time to 
obtain a result because culture is not necessary, but can only detect a limited number of 
prespecified targets. Small studies have shown that array comparative genomic 
hybridization (aCGH) can detect all unbalanced chromosomal abnormalities as well as 
smaller deletions and duplications that cannot be detected with routine cytogenetic 
analysis. Should aCGH screening be used instead of karyotyping to diagnose prenatal 
chromosomal abnormalities in pregnant patients with abnormal ultrasound? 
 
Methods:  An exhaustive search of available medical literature from the past 5 years was 
conducted using Medline-OVID, CINAHL, Web of Science. Key words included: 
comparative genomic hybridization, pregnancy, abnormal ultrasound, prenatal ultrasound 
and ultrasound. Relevant articles were assessed for quality using GRADE. 
 
Results:  Two studies met inclusion criteria and were used in this review.  The first is a 
large prospective, comparison to gold standard (karyotyping).  This study compared 
prenatal diagnostic samples, and found microarray (aCGH) was equivalent to standard 
karyotype analysis for common aneuploidies and found additional clinically relevant 
information when patients had abnormal ultrasounds.  The second study was a 
prospective study of over 5000 pregnancies and again additional clinical significant 
findings were found using aCGH. 
 
Conclusion:  Array comparative genomic hybridization should be considered for all 
patients who wish to undergo invasive prenatal screening and should be offered to all 
patients with abnormal prenatal ultrasounds.   Adequate genetic counseling should be 
provided by a trained professional in all cases.  A cost analysis should be done comparing 
tests.   
 
Keywords: Array comparative genomic hybridization, pregnancy, abnormal ultrasound, 
prenatal diagnosis  
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Array Comparative Genomic Hybridization (aCGH): A Diagnostic Test for the 
Prenatal Diagnosis of Chromosomal Abnormalities with Emphasis on Patients with 
Abnormal Ultrasounds 
 
BACKGROUND 
The decision to undergo invasive prenatal screening can be difficult.  There are 
many factors that may lead to the decision: family or personal history of birth defects, the 
increased risk of chromosomal abnormalities, a future life with an affected child, and the 
options for earlier termination.  When patients are at increased risk for chromosomal 
abnormalities, they are offered chorionic villus sampling (CVS) in their first trimester or 
amniocentesis in the second and third trimester.1,2 The standard screening test is 
conventional metaphase karyotype analysis of chromosomes to detect aneuploidies and 
large structural changes in the prenatal diagnosis, limitations include: inconsistent 
identification of microscopic gene defects and requires cell culture, which takes seven to 
fourteen days to obtain.2-4 The use of fluorescent in situ hybridization (FISH) reduces the 
time to obtain a result because culture is not necessary, but can only detect a limited 
number of prespecified targets.3  
 Array comparative genomic hybridization (aCGH), also known as microarray, has 
been successful in the diagnosis of genomic rearrangements in children and adults with 
birth defects, dysmorphic features, and developmental delay or neurobehavioral 
abnormalities.5 This led to the use in the prenatal setting. Some smaller studies2,3 have 
shown some clinical benefit to using aCGH in the prenatal setting, and it has the ability to 
detect all unbalanced chromosomal abnormalities as well as smaller deletions and 
duplications that would be missed on standard karyotype. Furthermore, culture is not 
needed, and the entire genome can be assessed, unlike FISH. However, aCGH does 
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however have limitations. Several studies 2,3,6-9 show that aCGH testing was unable to 
diagnose balanced translocations, inversions and alterations, and has difficulty 
diagnosing all polyploidy conditions and low-level mosaicism. Additionally, studies have 
shown that copy number variants (CNV) of uncertain clinical significance as well as 
benign CNVs may be found during testing.2,3,6-9 The studies cited above have shown the 
benefits of  adding aCGH testing for prenatal diagnosis but current ACOG guidelines 
suggest that it be additive for patients with  abnormal ultrasounds with normal 
karyotypes.10 The purpose of this search was to concentrate specifically on studies with a 
large patient population as well as large subpopulations of patients with abnormal 
ultrasounds and to answer the question; should aCGH screening be used instead of 
karyotyping to diagnose prenatal chromosomal abnormalities in pregnant patients with 
abnormal ultrasounds? 
METHODS 
An exhaustive search of available medical literature from the past 5 years was 
conducted using Medline-OVID, CINAHL, and Web of Science. Key words included: 
comparative genomic hybridization, pregnancy, abnormal ultrasound, prenatal ultrasound 
and ultrasound. Search results were narrowed eliminating articles that were not in 
English, non-human, articles prior to 2009 and n< 1000 when pertaining to abnormal 
ultrasounds.  Bibliographies of the articles were also searched for relevant sources.  
Articles with large patient populations with abnormal prenatal ultrasounds and aCGH 
screening compared to standard karyotype were included. Relevant articles were 
critically reviewed and assessed for quality using Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE).11 
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RESULTS 
The initial search yielded 29 articles for review. After assessing the articles for 
relevancy to the topic, eight articles were further reviewed based on the inclusion criteria. 
Of these, two articles met both inclusion and exclusion criteria. Both articles are large 
prospective studies.12,13 See Table I 
Chromosomal Microarray versus Karyotyping for Prenatal Diagnosis 
 This large prospective and blinded study12 assessed the ability for microarray 
analysis (aCGH) to detect common chromosome abnormalities and determine what 
additional clinically relevant information can be provided by microarray analysis. 
Training, microarray kits and reagents were provided by Agilent Technologies and 
Affymetrix free of charge and were not involved in the actual study. Data analysis was 
performed by the authors.  Integrated Genetics had no part in the microarray analysis but 
did receive funding to perform conventional cytogenetic data (karyotyping). Primary 
outcomes assessed microarray results as being a true positive, true negative, false positive 
or false negative when compared to standard karyotyping for identifying common 
autosomal and sex-chromosome aneuploidies. Secondary outcomes included: the number 
and classification of CNV identified by microarray in the presence of a normal karyotype, 
the success of microarray analysis, and the ability for microarray to identify uncommon 
cytogenetic abnormalities, such as, polyploidy, marker chromosomes or rearrangements 
that would normally be seen on karyotype.12 
 Starting in October 2008 and finishing in July 2011, 6537 women were screened 
for this study. The study enrolled 4406 women with singleton gestation and utilized 29 
diagnostic centers where patients received CVS or amniocentesis. Eligibility for testing 
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included: advanced maternal age, positive aneuploidy screening test and structural 
anomalies on ultrasound.  Appropriate pretest genetic counseling was performed. Of this 
group 4282 had both karyotype and microarray analysis. One hundred and twenty four 
samples were excluded due to maternal contaminations, culture or karyotype analysis 
failure, microarray failure, or mosaic karyotypes. At least 2mg of chronic-villus tissue 
and approximately 7 to 10 ml of amniotic fluid were deidentified and sent with parental 
blood samples to laboratories at Baylor College Medicine, Columbia University, Emory 
University, or Signature Genomic Laboratories for microarray analysis. Integrated 
Genetics received all CVS and amniocentesis results and karyotype results were reported 
to the referring physician.12 
 Two array platforms were used; Agilent 4-plex array and Affymetrix Genome 
wide Human SNP Array 6.0.  The majority 71% were performed on Agilent 4-plex array. 
When Affymetrix was used analysis software was used to mask the data to match 
resolution and coverage of the Agilent platform. Initially both cultured and uncultured 
samples were analyzed. Acceptable uncultured results were observed in first 259 CVS 
and 275 amniotic fluid samples so the remaining samples were performed uncultured, 
which allows for a faster turnaround time. When CNV were detected parental blood 
samples were used to determine if these were inherited or de novo.  De novo findings 
were checked with normal karyotype and by FISH analysis.12 
  George Washington University Biostatistics Center was used for data 
coordination. This independent coordination center received both array and karyotype 
results from each laboratory. SAS software was used in the analysis. CNVs were assessed 
by the study’s clinical geneticist and all CNVs not judged as likely benign were sent to an 
  - 11 -  
independent clinical advisory group for review and classification. All variants determined 
clinically important were reported to patients.12  
 Standard karyotype revealed 317 common autosomal and 57 sex-chromosome 
aneuploidies. One hundred percent of these findings were also found using microarray 
analysis, in addition microarray revealed clinically significant segmental aneuploidies not 
detected on standard karyotype. Of the structural rearrangements, microarray also 
discovered all 22 unbalanced and rearrangements that were revealed on standard 
karyotype, however, did not reveal any balanced rearrangements or triploid samples.  
Microarray identified 1399 samples CNV of these 165 were looked at more closely and 
35 were on a predetermined pathogenic list. Further analysis revealed 61 more CNVs that 
were clinically significant. Overall 96 of the 3822 samples with normal karyotypes had 
clinically significant CNVs (2.5%; 95% CI 2.1 -3.1).12 
Subgroups results included: advanced maternal age, positive down syndrome 
screening, anomaly on ultrasound, and other. Microarray found additional clinically 
significant findings in all categories. The largest percentage was noted in patients with 
anomaly on ultrasound. A total of 1109 patients were enrolled for this indication and 755 
had normal karyotypes, of that group 45 were determined to have clinically significant 
findings on microarray (6.0%; 95% CI 4.5-7.9).12 
Experience with Microarray-based Comparative Genomic Hybridizations for 
Prenatal Diagnosis in Over 5000 Pregnancies   
 In this large prospective study13 the authors attempt to demonstrate the advantages 
of aCGH over karyotyping for prenatal diagnosis of clinically relevant chromosome 
alterations. Starting in July 2004 through December 2011 prenatal samples from amniotic 
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fluid, CVS, fetal blood and products of conception were sent directly to the authors’ 
laboratory for analysis. A total of 5003 samples were tested from the US and abroad.  The 
indication for array testing or indication of study (ISF) included: abnormal karyotype, 
family history of a parent known to carry a chromosome rearrangement or imbalance, 
fetal demise, abnormal first or second trimester screen, abnormal ultrasound, other family 
history of genetic  conditions, advanced maternal age, paternal anxiety, and other/not 
specified.  The largest IFS was abnormal ultrasound with 2858 patients.13   
Using the laboratory data base and Genoglyphix database, samples were 
identified as normal (no clinically significant CNVs or with or without benign CNVs), 
with variant of uncertain significance (VOUS), or abnormal (clinically significant). Each 
case was reviewed by the authors MPD and JAR and categorized based on the results 
discussed above as well as their IFS. The latter was categorized based on the patient’s 
most significant risk factor. Samples with unclear results were reviewed further by 
authors LGS and JAR and reassigned if indicated. Abnormal ultrasound were further 
classified according to clinical phenotype.13,14 
 Samples with unclear results were review by two different authors LGS and JAR 
and reassigned to either normal or abnormal groups. Abnormal results were then 
reviewed by author JAR and stratified based on the size of the alteration. An overall 
detection rate of clinically significant results was 5.3 % with a two-tailed p=0.024. Of the 
total samples 56.3 % or 2819 were referred with normal karyotypes and the detection rate 
increased to 5.5% among this category when the bias of family history and fetal demise 
were excluded (5.5%, 140/2533). In addition 71% of the abnormalities identified were < 
10Mb and would likely not be seen on standard karyotype. Microarray also detected 33 
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samples with abnormalities > 10Mb that had normal karyotypes.  When IFS was an 
abnormal ultrasound, the percent of additional significant clinically relevant CNVs 
increased to 6.5% in the presence of a normal karyotype.13 
DISCUSSION 
 Microarray-based comparative genomic hybridization has been shown in many 
small prospective studies and case studies to add clinically significant detection rates for 
chromosomal abnormalities in the prenatal setting.2,6-9,15,16 Currently ACOG supports the 
use of aCGH testing but not as a first line test in the prenatal setting.1,10 These two large 
prospective studies12,13give additional evidence to support past findings.  Additionally, 
the large patient population includes a larger subpopulation with abnormal ultrasound to 
help answer the question: Should aCGH screening be used instead of karyotyping to 
diagnose prenatal chromosomal abnormalities in pregnant patients with abnormal 
ultrasound? 
 When comparing aCGH with standard karyotype for the prenatal diagnosis of 
common aneuploidies Wapner et al12 showed equivalence.  Furthermore, both studies12,13 
revealed clinically relevant information that was not found on standard karyotype.  In the 
presence of an abnormal prenatal ultrasound and normal karyotype Wapner et al12 found 
an additional 6% of clinically significant findings and Shaffer et al13 had similar results 
6.5%.  Furthermore, Wapner et al12 found that uncultured samples are just as efficacious, 
therefore avoiding the additional time needed for culture.12,13   
However, both studies12,13 established that there are some limitations.  This 
includes the ability for aCGH to fined VOUS, and its inability to identify triploidy or 
balanced translocations. Wapner et al12does report that a post hoc review reveled that use 
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single nucleotide polymorphism (SNP) probes would have identify triploid cases and thus 
recommends using SNP probes with testing. Mutually, these studies agree that 
appropriate pre and post genetic testing should be required to prepare patients for 
potential result.12,13    
 Both studies12,13 were large prospective studies. Additionally, Wapner et al12 was 
a blind comparison to a gold standard (karyotype).  Each study characterized CNVs into 
four similar categories. Wapner et al12 was a well conducted study that utilized blinding 
when applicable and used an independent clinical advisory group to analyze all samples 
that were not judged as “likely benign.”  The Shaffer et al13 study did not mention 
blinding and all results were reviewed by the study authors, which could contribute to 
some bias.  These limitations were taken into consideration for the GRADE analysis. See 
Table II  
A cost analysis was not performed in either study.12,13 It would be important to 
determine if this would be a cost effective method when compared to standard 
karyotyping alone or with FISH analysis.   
CONCLUSION 
Array comparative genomic hybridization should be considered for all patients 
who wish to undergo invasive prenatal screening and should be offered to all patients 
with abnormal prenatal ultrasounds.  This test has shown to be equivalent to standard 
karyotype analysis in determining common aneuploidies and is able to find clinically 
relevant abnormalities that would otherwise be missed on karyotype.  Adequate genetic 
counseling should be provided by a trained professional in all cases and should include 
the benefits and limitations of aCGH testing. As aCGH becomes more utilized the 
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amount of variants of uncertain significance will decrease and thereby decreasing the 
challenge of genetic counseling and anxiety placed on the parents.    
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Table I. Characteristics of Reviewed Studies 
 
Table II. Summary of Findings 
 
 
 
 
 
 
 
 
  
 Outcomes 
Studies  
Ability to identify  abnormal autosomal and sex-
chromosome aneuploidies 
Ability for aCGH identify chromosomal 
abnormalities with abnormal prenatal ultrasound 
in patients with normal Karyotype  
Microdeletion or duplication of clinical 
significance  found on aCGH with normal 
Karyotype 
Karyotype aCGH   
Wapner et al12 374 374 6%; 95% CI, 5 to 7.9 2.5% 95%  CI, 2.1 to 3.1 
Shaffer et al13 * * 6.2% 128/2052 5.5% 
Quality Assessment  
 Downgrade Criteria 
Quality 
 Study Design Total patients 
Patients with 
abnormal 
ultrasound 
Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Wapner et al12 
 
Prospective, bind 
comparison to 
gold standard  
4406 1109   No serious limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies low Moderate  
Shaffer et al13  prospective 5000 2858 No mention of blinding 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies possible Low  
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